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ABSTRACT
A series of benzo[d]thiazole-5- and 6-sulfonamides has been synthesized and investigated for the inhibition
of several human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms, using ethoxzolamide (EZA) as lead mol-
ecule. 2-Amino-substituted, 2-acylamino- and halogenated (bromo-and iodo-derivatives at the heterocyclic
ring) compounds led to several interesting inhibitors against the cytosolic hCA I, II and VII, as well as the
transmembrane, tumor-associated hCA IX isoforms. Several subnanomolar/low nanomolar, isoform-selective
sulfonamide inhibitors targeting hCA II, VII and IX were detected. The sharp structure–activity relationship
for CA inhibition with this small series of derivatives, with important changes of activity observed even
after minor changes in the scaffold or at the 2-amino moiety, make this class of scarcely investigated sulfo-
namides of particular interest for further investigations.
ARTICLE HISTORY
Received 22 June 2017
Revised 12 July 2017






The carbonic anhydrases (CAs, EC 4.2.1.1) are a superfamily of met-
alloenzymes which catalyze the interconversion between CO2 and
bicarbonate by using a metal hydroxide nucleophilic mechan-
ism1–9. Seven distinct genetic CA families are known to date, the
a-h-CAs, which differ in their preference for metal ions used within
the active site for performing the catalysis, their oligomerization
state, but most importantly the three-dimensional fold of the pro-
tein1–12. In all cases, the apoenzymes are devoid of catalytic activ-
ity, the presence of the metal ion being essential both for catalysis
as well as binding of inhibitors, many of which have biomedical
applications10–29.
Sulfonamides are the most important class of CA inhibitors
(CAIs)10–19, with several compounds such as acetazolamide (AAZ),
methazolamide (MZA), ethoxzolamide (EZA), sulthiame (SLT),
dichlorophenamide (DCP), dorzolamide (DZA), brinzolamide
(BRZ), sulpiride (SLP), zonisamide (ZNS), topiramate (TPM) (a
sulfamate, not sulfonamide), celecoxib (CLX) and valdecoxib
(VLX) (Figure 1).
Compounds AAZ–VLX may be considered as first/second gen-
eration CAIs. Their main problem is that they indiscriminately
inhibit most of the human isoforms known to date30–39. Indeed,
16 such isozymes were described in non-primates, CA I–XV with
two V-type isoforms, CA VA and CA VB, and 15 isoforms are
known in primates, as CA XV is not expressed in these mam-
mals1–9. The nonselective inhibition of most CA isoforms by the
first/second generation sulfonamide CAIs is the reason why a




Anhydrous solvents and all reagents were purchased from
Sigma-Aldrich, Alfa Aesar and TCI. All reactions involving air- or
moisture-sensitive compounds were performed under a nitrogen
atmosphere using dried glassware and syringes techniques to
transfer solutions. Nuclear magnetic resonance (1H NMR, 13C NMR)
spectra were recorded using a Bruker Avance III 400MHz spec-
trometer in DMSO-d6. Chemical shifts are reported in parts per
million (ppm), and the coupling constants (J) are expressed in
Hertz (Hz). Splitting patterns are designated as follows: s, singlet;
d, doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet;
dd, double of doublets, and dt, double of triplets. The assignment
of exchangeable protons (OH and NH) was confirmed by the add-
ition of D2O. Analytical thin-layer chromatography (TLC) was car-
ried out on Merck silica gel F-254 plates. Flash chromatography
purifications were performed on Merck Silica gel 60 (230–400
mesh ASTM) as the stationary phase, and ethyl acetate (EtOAc)/
n-hexane were used as eluents. Melting points (m.p.) were carried
out in open capillary tubes and are uncorrected.
4-Thioureido-benzenesulfonamide (1)
Sulfanilamide (2.0 g, 1.0 eq) was dissolved in a freshly prepared
3.5M hydrochloric acid aqueous solution under gentle warming.
The solution was cooled down to r.t. and potassium thiocyanate
(1.0 eq) was added to reaction mixture then the mixture was
heated at 90 C for 3 h, cooled to r.t. to form precipitate which
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was filtered-off, washed with water, and dried under vacuum to
afford the titled compound.
White solid, 93% yield; dH (400MHz, DMSO-d6) 7.30 (2H, s), 7.70
(2H, d, J 8.8), 7.77 (2H, d, J 8.8), 10.01 (1H, s, exchange with D2O,
NH); dC (100MHz, DMSO-d6) 122.7, 127.2, 139.8, 143.4, 182.2; m/z
(ESI positive) 232.01 [MþH]þ. Experimental in agreement with
reported data40.
3-Thioureidobenzenesulfonamide (3)
3-Aminobenzensulfonamide (5.0 g, 1 eq) was dissolved in a freshly
prepared 3.5M hydrochloric acid aqueous solution by gentle
warming, followed by treatment with potassium thiocyanate (1.0
eq) at r.t. and then heated to 90 C for 12 h. The reaction mixture
was cooled-down to r.t. and extracted with EtOAc (3 5.0ml). The
combined organic layers were washed with H2O (3 5.0ml), dried
over Na2SO4, filtered and concentrated to obtain a residue that
was purified by silica gel column chromatography eluting with
EtOAc/n-Hexane 70% v/v, followed by trituration with dichlorome-
thane (DCM) to afford the titled compound.
White solid, 47% yield; dH (400MHz, DMSO-d6) 7.39 (2H, s,
exchange with D2O, SO2NH2), 7.56 (2H, m), 7.74 (1H, dt, J 1.8, 7.8),
7.96 (1H, d, J 1.8), 9.97 (1H, s, exchange with D2O, NH); dC
(100MHz, DMSO-d6) 120.5, 122.0, 126.7, 130.0, 140.8, 145.2, 182.4;
m/z (ESI positive) 232.0 [MþH]þ. Experimental in agreement with
reported data41.
2-Aminobenzo[d]thiazole-6-sulfonamide (2)
A suspension of 4-thioureido-benzenesulfonamide 1 (1.0mmol, 1.0
eq) in CHCl3 (4.0ml) was treated with Br2 (1.5 eq) drop-wise.
The mixture was heated to 70 C for 4.5 h, cooled-down to r.t. and
the solvents were removed under reduced pressure to give a solid
that was dissolved in H2O (5.0ml). The aqueous solution was
treated with NH4OH and stirred at 90 C for 1 h. The formed pre-
cipitate was filtered-off, washed with H2O and dried under vacuum
to afford the titled compound.
White solid, 80% yield; dH (400MHz, DMSO-d6) 7.23 (2H, s,
exchange with D2O, SO2NH2), 7.45 (1H, d, J 8.4), 7.69 (1H, dd, J 8.4,
1.8), 7.89 (2H, s, exchange with D2O, NH2), 8.15 (1H, d, J 1.8); dC
(100MHz, DMSO-d6) 118.0, 120.1, 124.6, 131.8, 137.2, 156.0, 170.3;
m/z (ESI positive) 230.00 [MþH]þ. Experimental in agreement with
reported data41.
2-Aminobenzo[d]thiazole-5-sulfonamide (4)
A suspension of 3 (1.2 g, 1.0 eq.) in CHCl3 (15.0ml) was treated
with Br2 (1.5 eq) in CHCl3 (1.0ml) drop-wise. The mixture was
heated to 70 C for 12 h, cooled down to r.t., the solvent elimi-
nated in vacuum to give a residue that was dissolved in H2O
(5.0ml) and treated with NH4OH, followed by 1 h stirring at 90 C.
The cooled reaction mixture was filtered, washed with water and
dried under vacuum to afford the titled compound.
White solid, 45% yield; dH (400MHz, DMSO-d6) 7.42 (1H, t,
J 8.0), 7.49–7.56 (4H, m, 2H exchange with D2O, SO2NH2), 7.69 (2H,
s, exchange with D2O, NH2); dC (100MHz, DMSO-d6) 120.39, 121.4,
126.7, 128.5, 137.7, 155.3, 169.7; m/z (ESI positive) 230.00 [MþH]þ.
2-Amino-4-bromobenzo[d]thiazole-6-sulfonamide (5)
A suspension of 2 (0.75 g, 1 eq) in chloroform (15.0ml) was treated
with a solution of Br2 (8.0 eq) in chloroform (2.5ml) drop-wise.
Figure 1. Clinically used CAIs of the sulfonamide and sulfamate type10–19.
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The mixture was heated to 70 C for 4 h. After cooling to r.t. the
solvents were removed under reduced pressure. The obtained
solid was dissolved in water (5.0ml) and treated with ammonium
hydroxide (pH ¼10), then the reaction mixture stirred for 1 h at
90 C. The precipitated solid was filtered under vacuum, washed
with H2O (3 5.0ml), then with n-Hexane (3 3.0ml) and dried to
afford the titled compound.
Orange solid, 68% yield; dH (400MHz, DMSO-d6) 7.35 (2H, s,
exchange with D2O, SO2NH2), 7.89 (1H, s), 8.17 (1H, s), 8.26 (2H, s,
exchange with D2O, NH2); dC (100MHz, DMSO-d6) 110.7, 119.7,
127.6, 132.6, 138.1, 154.5, 170.9; m/z (ESI positive) 307.9 [MþH]þ.
2-Amino-4-bromobenzo[d]thiazole-5-sulfonamide (6)
A suspension of 4 (0.2 g, 1.0 eq) in chloroform (4.0ml) was treated
with a solution of Br2 (6.0 eq) in chloroform (1.0ml) drop-wise.
The mixture was heated to 70 C for 12 h. After cooling to r.t. the
solvents were removed under reduced pressure. The obtained
solid was dissolved in water (5.0ml) and treated with ammonium
hydroxide (pH ¼10), then the reaction mixture stirred for 1 h at
90 C. After cooling, the reaction mixture was extracted with
EtOAc (3 5ml). The combined organic layers were washed with
H2O (3 5.0ml), dried over Na2SO4, filtered and concentrated to
obtain a residue that was purified by silica gel column chromatog-
raphy eluting with EtOAc/n-Hexane 70% v/v to afford the titled
compound.
Orange solid, 19% yield; dH (400MHz, DMSO-d6) 7.40 (1H, d, J
8.4), 7.66 (2H, s, exchange with D2O, SO2NH2), 7.69 (1H, d, J 8.4),
8.08 (2H, s, exchange with D2O, NH2); dC (100MHz, DMSO-d6)
114.3, 120.6, 128.8, 129.8, 137.1, 152.9, 170.1; m/z (ESI negative)
305.7 [M-H].
2-Amino-4-iodobenzo[d]thiazole-6-sulfonamide (7)
A solution of 2 (0.3 g, 1.0 eq) in methanol (3.0ml) was treated
with iodine monochloride (4.0 eq) in methanol (1.0ml) drop-wise.
The mixture was heated to reflux temperature for 12 h. After cool-
ing to room temperature, the reaction mixture was extracted with
EtOAc (3 5.0ml). The combined organic layers were washed with
H2O (3 5.0ml), dried over Na2SO4, filtered and concentrated to
obtain a residue that was purified by silica gel column chromatog-
raphy eluting with EtOAc/n-Hexane 70% v/v to afford the titled
compound.
Dark orange solid, 31% yield; dH (400MHz, DMSO-d6) 7.31 (2H,
s, exchange with D2O, SO2NH2), 8.06 (1H, d, J 2.0), 8.16 (1H, d, J
2.0), 8.21 (2H, s, exchange with D2O, NH2); dC (100MHz, DMSO-d6)
84.4, 119.9, 129.9, 133.1, 138.3, 157.0, 169.7; m/z (ESI positive)
355.9 [MþH]þ.
2-Amino-4-iodobenzo[d]thiazole-5-sulfonamide (8)
A solution of 4 (0.2 g, 1.0 eq) in methanol (3.0ml) was treated
with a solution of iodine monochloride (4.0 eq) in methanol
(1.0ml) drop-wise. The mixture was heated to reflux temperature
for 12 h. After cooling to room temperature, the reaction mixture
was extracted with EtOAc (3 5ml). The combined organic layers
were washed with H2O (3 5.0ml), dried over Na2SO4, filtered and
concentrated to obtain a residue that was purified by silica gel
column chromatography eluting with EtOAc/n-Hexane 70% v/v to
afford the titled compound.
Dark orange solid, 16% yield; dH (400MHz, DMSO-d6) 7.25 (1H,
d, J 8.0), 7.63 (2H, s, exchange with D2O, SO2NH2), 7.87 (1H, d, J
8.0), 8.03 (2H, s, exchange with D2O, NH2); dC (100MHz, DMSO-d6)
84.5, 119.9, 129.9, 133.2, 138.3, 157.0, 169.7; m/z (ESI positive)
355.8 [MþH]þ.
N-(6-sulfamoylbenzo[d]thiazol-2-yl)acetamide (9)
A solution of 2 (1.0 g, 1.0 eq) in acetic acid (2.0ml) was cooled to
0 C followed by drop-wise addition of acetic anhydride (1.2 eq).
The reaction mixture was refluxed for 3 h then excess of solvents
were removed under reduced pressure to obtain a residue which
was washed with Et2O (3 5ml) to obtain titled compound.
White solid, 96% yield; dH (400MHz, DMSO-d6) 2.27 (3H, s), 7.39
(2H, s, exchange with D2O, SO2NH2), 7.90 (2H, d, J 1.2), 8.50 (1H, t,
J 1.2), 12.59 (1H, s, exchange with D2O, NH); dC (100MHz, DMSO-
d6) 23.7, 121.0, 121.4, 124.8, 132.4, 139.9, 151.7, 161.9, 170.7; m/z
(ESI positive) 272.0 [MþH]þ.
N-(4-bromo-6-sulfamoylbenzo[d]thiazol-2-yl)acetamide (10)
A solution of 5 (0.1 g, 1.0 eq) in acetic acid (0.5ml) was cooled to
0 C followed by drop-wise addition of acetic anhydride (1.2 eq)
then the mixture was refluxed for 3 h. The excess of solvents was
removed under reduced pressure. The obtained solid was treated
with sodium bicarbonate (1 N, 3.0ml), then the reaction mixture
was extracted with EtOAc (3 5ml). The combined organic layers
were washed with H2O (3 5.0ml), dried over Na2SO4, filtered and
concentrated under reduced pressure to afford the titled
compound.
Orange solid, 93% yield; dH (400MHz, DMSO-d6) 2.24 (3H, s),
7.44 (2H, s, exchange with D2O, SO2NH2), 8.05 (1H, s), 8.50 (1H, s),
12.59 (1H, s, exchange with D2O, NH); dC (100MHz, DMSO-d6) 23.6,
114.1, 120.5, 127.5, 133.2, 140.8, 149.8, 162.7, 171.0; m/z (ESI posi-
tive) 349.8 [MþH]þ.
N-(5-sulfamoylbenzo[d]thiazol-2-yl)acetamide (11)
A solution of 4 (0.1 g, 1.0 eq) in acetic acid (0.5ml) was cooled to
0 C followed by drop-wise addition of acetic anhydride (1.2 eq)
then the mixture was refluxed for 3 h. The excess of solvents was
removed under reduced pressure. The obtained solid was treated
with sodium bicarbonate (1 N, 3ml), then the reaction mixture was
extracted with EtOAc (3 5ml). The combined organic layers were
washed with H2O (3 5.0ml), dried over Na2SO4, filtered and con-
centrated under reduced pressure to afford the titled compound.
White solid, 89% yield; dH (400MHz, DMSO-d6) 2.27 (3H, s), 7.66
(1H, t, J 7.8), 7.71 (2H, s, exchange with D2O, SO2NH2), 8.80 (1H,
dd, J 7.8, 1.0), 7.98 (1H, dd, J 7.8, 1.0), 12.45 (1H, s, exchange with
D2O, NH); dC (100MHz, DMSO-d6) 23.6, 122.7, 124.6, 127.1, 128.8,
138.6, 150.9, 161.5, 170.6; m/z (ESI positive) 272.0 [MþH]þ.
2-((6-Sulfamoylbenzo[d]thiazol-2-yl)carbamoyl)benzoic acid (12)
A solution of 2 (0.3 g, 1.0 eq) in dry DMF (3.0ml) was treated with
phthalic anhydride (1.0 eq), then the mixture was refluxed for 4 h.
The reaction mixture was extracted with EtOAc (3 5.0ml). The
combined organic layers were washed with H2O (3 5.0ml), dried
over Na2SO4, filtered and concentrated under reduced pressure to
afford the corresponding pure mixture of 2 isomers in (50:50) as
evidenced by 1H NMR integration.
White solid, 100% yield; dH (400MHz, DMSO-d6) 7.41 (2H, s,
exchange with D2O, SO2NH2), 7.51 (2H, s, exchange with D2O,
SO2NH2), 7.67–7.77 (4H, m), 7.93–8.03 (7H, m), 8.11–8.13 (2H, m),
8.22 (1H, d, J 8.4), 8.56 (1H, s, exchange with D2O, NH), 8.71 (1H, d,
J 1.6, exchange with D2O, NH); dC (100MHz, DMSO-d6) 121.0,
121.2, 121.5, 123.4, 124.8, 125.0, 125.1, 129.0, 130.6, 130.8, 131.3,
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131.9, 132.5, 132.9, 133.2, 136.5, 137.0, 140.0, 141.5, 151.7, 151.8,
156.2, 162.1, 165.2, 167.8, 169.6; m/z (ESI positive) 377.9 [MþH]þ.
CA inhibition
An Applied Photophysics stopped-flow instrument has been used
for assaying the CA catalyzed CO2 hydration activity
42. Phenol red
(at a concentration of 0.2mM) has been used as indicator, working
at the absorbance maximum of 557 nm, with 20mM Hepes (pH
7.5) as buffer, and 20mM Na2SO4 (for maintaining constant the
ionic strength), following the initial rates of the CA-catalyzed CO2
hydration reaction for a period of 10–100 s. The CO2 concentra-
tions ranged from 1.7 to 17mM for the determination of the kin-
etic parameters and inhibition constants. For each inhibitor, at
least six traces of the initial 5–10% of the reaction have been used
for determining the initial velocity. The uncatalyzed rates were
determined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (0.1mM) were prepared
in distilled–deionized water and dilutions up to 0.01 nM were
done thereafter with the assay buffer. Inhibitor and enzyme solu-
tions were preincubated together at room temperature (15min)
prior to assay, in order to allow for the formation of the E–I com-
plex. Data from Table 1 were obtained after 15min incubation of
enzyme and inhibitor, as for all sulfonamides reported earlier43–50.
The inhibition constants were obtained by non-linear least-squares
methods using PRISM 3 and the Cheng–Prusoff equation, as
reported earlier51–55 and represent the mean from at least three
different determinations. All CA isoforms were recombinant ones
obtained in-house as reported earlier51–60.
Results and discussion
Chemistry
Most of the CAIs generated in our group over the last two deca-
des were designed by using the tail approach15,32,33. By choosing
various functionalities that are appended on the scaffold of aro-
matic/heterocyclic sulfonamides in such a way as to interact with
the middle and rim parts of the CA active site, a large number of
isoform-selective CAIs were obtained15–36. Here on the other hand,
we decided to explore a variant of the ring approach1,4, using
ethoxzolamide (EZA) (Figure 1) as lead molecule. A series of ben-
zothiazole-6-sulfonamides are reported here, which differ from
EZA mainly by the position of the sulfamoyl moiety and by the
presence of various substituents at the heterocyclic ring, in various
positions (Scheme 1).
Sulfanilamide (SA)/metanilamide (MA) were reacted with potas-
sium isocyanate in the presence of HCl, leading to the correspond-
ing isothiocyanato-benzenesulfonamides 1 and 3, respectively.
Bromination of these key intermediates led to the ring closure and
formation of the regiomeric benzothiazole sulfonamides 2 and 4,
respectively (Scheme 1). These compounds were acetylated and/or
halogenated, leading to the small library of derivatives shown in
Scheme 1 (see Experimental for details). Four of these derivatives
have the sulfamoyl moiety in the 5 position of the benzothiazole
ring, whereas the remaining ones in the 6 position (Scheme 1).
Carbonic anhydrase inhibition
The synthesized compounds 1–12 were investigated for their
inhibitory effects against four physiological relevant isoforms, i.e.
hCA I, II, VII and IX, by means of a stopped flow CO2 hydrase
assay42.
The following structure–activity relationship (SAR) can be drawn
from data of Table 1:
i. hCA I was inhibited by all these sulfonamides, with inhibition
constants ranging between 84.1 and 2327 nM. Two com-
pounds, 2 and 12, had KIs< 100 nM, and they have both
2-amino-benzothiazole-6-sulfonamide derivatives. However 2
has no substituents on the amino functionality, whereas 12
has the bulky phthaloyl-monoamide functionality, proving
thus that the SAR for inhibiting this isoform with sulfona-
mides investigated here is rather complex. Both these com-
pounds were around three–four times less effective hCA I
inhibitors compared to EZA (KI of 25 nM). Introduction of hal-
ogens on the benzothiazole scaffold of acetylation of the
amino group led to compounds with less effective hCA I
inhibitory properties compared to 2. The same was true for
the compounds from the benzothiazole-5-sulfonamide series.
For the simple derivatives, generally the 6-sulfamoyl deriva-
tives were more effective CAIs compared to the correspond-
ing 5-sulfamoyl ones (e.g. compare 2 and 4) whereas for the
halogeno-substituted ones the behavior was not so clear-cut,
with the bromoderivatives 5 and 6 behaving like the parent
aminoderivatives, whereas an opposite effect was observed
for the iododerivatives 7 and 8, case in which the 5-sulfona-
mide was a better inhibitor compared to the isomeric 6-
sulfonamide (Table 1).
ii. hCA II was effectively inhibited by sulfonamides investigated
here, with KIs in the range of 7.8–369 nM. The best inhibitors
were 2, 5–9, 11 and 12, with inhibition constants in the
range of 7.8–51.5 nM. They belong to both the 5- as well as
6-sulfonamide series. The 2-amino-benzothiazole-6-sulfona-
mide derivative 2 was already an effective hCA II inhibitor,
and its derivatization (acetylation and mono-phthaloylation)
led to even better inhibitors (compare 9, 12, and 2).
Halogenation of 2 led to very effective inhibitors, with both
the bromo-and iodo-derivatives 5, 7, having KIs of 8.7 and
15.1 nM, respectively. However, bromination of the acetylated
derivative 9 led to a strong loss of inhibitory effects in the
halogenated derivative 10. For the 5-sulfonamide series, the
situation was rather different. The parent compound,
2-amino-benzothiazole-5-sulfonamide derivative 4 was a
modest hCA II inhibitor, with an inhibition constant of
369 nM. Its derivatization by introduction of halogeno atoms
on the heterocyclic ring, as in 6 and 8, or the acetylation of
Table 1. Inhibition data of human CA isoforms hCA I, II, VII and IX with com-
pounds 1–12 in comparison with the standard sulfonamide inhibitors AAZ and




Compound hCA I hCA II hCA VII hCA IX
1 470.8 70.0 75.4 32.9
2 84.1 33.6 84.2 3.7
3 917.1 149.2 75.0 295.6
4 795.2 369.0 56.5 38.2
5 305.7 8.7 31.1 16.2
6 704.8 7.8 0.8 29.6
7 606.2 15.1 92.3 212.0
8 481.6 51.5 42.2 100.0
9 361.2 20.8 54.4 23.2
10 2327 210.7 80.6 34.4
11 340.6 42.0 81.5 32.6
12 97.1 13.5 46.5 10.0
AAZ 250.0 12.1 5.7 25.8
EZA 25.0 8.1 0.8 34.2
aMean from 3 different assays, by a stopped flow technique (errors were in the
range of ±5–10% of the reported values).
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the amino moiety, as in 11, led to a potent increase in the
inhibitory power, with the bromo-derivative 6 being one of
the best inhibitors on the series (KI of 7.8 nM, being more
effective than AAZ or EZA, see Table 1).
iii. Effective inhibition was observed also for the brain-associ-
ated, cytosolic isoform hCA VII, a recently validated target for
neuropathic pain61,62. The sulfonamides investigated here
showed KIs in the range of 0.8–92.3 nM. Most of these deriva-
tives were in fact medium potency inhibitors, with inhibition
constants of 42.2–92.3 nM, except 6 (KI of 0.8 nM) and 5 (KI of
31.1 nM). Both of them are the bromine derivatives of the iso-
meric 2-amino-benzothiazole-sulfonamides, with the 5-sul-
fonamide derivative 6 being 38.8 times a better hCA VII
inhibitor compared to the 6-sulfonamide one 5 (Table 1).
Compound 6 was equipotent to EZA for inhibiting this
isoform.
iv. The tumor-associated, transmembrane isoform hCA IX was
also effectively inhibited by these sulfonamides, with KIs in
the range of 3.7–295.6 nM (Table 1). The most effective inhib-
itors were 2, 4–6, and 9–12, with KIs in the range of
3.7–38.2 nM, the same range as the clinically used, standard
inhibitors AAZ and EZA (Table 1). By comparing the two
amino derivatives 2 and 4, it may be observed that in this
case the 6-sulfonamide 2 was around 10 times a better hCA
IX inhibitor compared to the isomeric 5-sulfonamide 4.
Halogenation of 2 generally led to a decrease of the inhibi-
tory potency, whereas acylation of the amino group had the
same effect (but the loss of potency was smaller). Rather
similar effects were observed for the 5-sulfonamide series,
except that the bromination led to a slight increase in the
hCA IX inhibitory power (compare 4 and 6).
v. Some of the reported sulfonamides tended to show some
selectivity for inhibiting one CA isoform over the remaining
ones. Examples in this sense are 6, which showed a good
hCA VII selective inhibition profile, 9, 10, 11, and 12, which
were effective hCA II and IX inhibitors, but weaker hCA I and
VII inhibitors. However, these compounds possess a rather
compact scaffold that probably binds deep within the CA
active site, where most amino acid residues are conserved
among the various isoforms. This is probably the reason why
they show a rather low isoform-selective inhibition profile, a
problem they share with most inhibitors of the first and
second generation, which have been designed by the ring
approach. As we stressed here and in other papers1,2,5, this
issue has been resolved by the using tail approach, which led
to many classes of isoform-selective CAIs63–65.
Conclusions
A small series of benzo[d]thiazole-5- and 6-sulfonamides has been
synthesized by following literature procedures, and investigated
for the inhibition of several hCA isoforms, using ethoxzolamide as
lead molecule. 2-Amino-substituted, 2-acylamino- and halogenated
(bromo-and iodo-derivatives at the heterocyclic ring) compounds
led to several interesting inhibitors against the cytosolic hCA I, II,
and VII, as well as the transmembrane, tumor-associated hCA IX
isoforms. Several subnanomolar/low nanomolar, isoform-selective
sulfonamide inhibitors targeting hCA II, VII and IX were detected.
The sharp structure–activity relationship for CA inhibition with this
small series of derivatives, with important changes of activity
observed even after minor changes in the scaffold or at the
2-amino moiety, make this class of scarcely investigated sulfona-
mides of particular interest for further investigations.
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